Skip to main content
. Author manuscript; available in PMC: 2023 Aug 9.
Published in final edited form as: Hepatology. 2023 Feb 20;78(1):243–257. doi: 10.1097/HEP.0000000000000307

Figure 6: p16 regulation of biliary FOXO1 expression in WT mice fed with HFD and in human NAFLD/NASH patients.

Figure 6:

FOXO1 immunostaining (green) increased in cholangiocytes (red) in WT HFD mice treated with control VM compared to CD control VM mice and FOXO1 immunoreactivity decreased in WT HFD mice treated with p16 VM compared to the control (A). FOXO1 (green) immunoreactivity was enhanced in cholangiocytes (red) of NAFLD, and NASH patients compared to the normal controls (B). Representative images for FOXO1/CK-19 staining for (A) were obtained from at least n = 6 images per group at 80 x magnification and 100x magnification for (B) representative of n = 4 for each group.